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http://dx.doi.org/10.1016/j.ccell.2015.04.008SUMMARYHeterozygous somatic mutations in the spliceosome gene U2AF1 occur in 11% of patients with myelodys-
plastic syndromes (MDS), the most common adult myeloid malignancy. It is unclear how these mutations
contribute to disease. We examined in vivo hematopoietic consequences of the most common U2AF1
mutation using a doxycycline-inducible transgenic mouse model. Mice expressing mutant U2AF1(S34F)
display altered hematopoiesis and changes in pre-mRNA splicing in hematopoietic progenitor cells by whole
transcriptome analysis (RNA-seq). Integration with human RNA-seq datasets determined that common
mutant U2AF1-induced splicing alterations are enriched in RNA processing genes, ribosomal genes, and
recurrently mutatedMDS and acutemyeloid leukemia-associated genes. These findings support the hypoth-
esis that mutant U2AF1 alters downstream gene isoform expression, thereby contributing to abnormal hema-
topoiesis in patients with MDS.INTRODUCTION
Myelodysplastic syndromes (MDS) are the most common
myeloid malignancy of the elderly, with approximately 10,000
new cases occurring in the United States annually (Ma, 2012).
MDS are a heterogeneous group of clonal hematopoietic stem
cell disorders characterized by peripheral blood cytopenias,
with up to 30% of patients experiencing progression to second-
ary acutemyeloid leukemia (AML) (Troy et al., 2014). Mutations in
spliceosome genes have been identified in over half of MDS pa-
tient bonemarrow samples, making it the most common class of
genes mutated in MDS (Damm et al., 2012; Graubert et al., 2012;
Papaemmanuil et al., 2011; Thol et al., 2012; Visconte et al.,
2012; Walter et al., 2013; Yoshida et al., 2011). The recurrently-Significance
Mutations in spliceosome genes occur in up to 50% of patie
perturbations in pre-mRNA splicing contribute to disease patho
mutation in the spliceosome gene U2AF1 and observed hemat
also occur in patients with MDS or acute myeloid leukemia. Co
genes, ribosomal genes, and recurrently mutated genes in mye
cesses and pathways that may functionally contribute tomutan
changes in the same genes are induced by other MDS-associ
target genes in MDS.mutated spliceosome genes encode factors that are involved
in the recognition of the 30-intronic splice site and are mutually
exclusive of one another in patient samples (Haferlach et al.,
2014; Papaemmanuil et al., 2013; Walter et al., 2013; Yoshida
et al., 2011), implying that they may contribute similarly to MDS
pathogenesis or, alternatively, may not be tolerated by a cell
when they co-occur.
Our group and others identified mutations in U2AF1 (U2 small
nuclear RNA auxiliary factor 1) in 11% of patients with MDS,
making it one of the most commonly mutated genes in this
disease (Graubert et al., 2012; Yoshida et al., 2011). In addition,
U2AF1mutations typically occur in the founding clone, suggest-
ing they may play an important role in disease initiation (Hafer-
lach et al., 2014; Papaemmanuil et al., 2013; Walter et al.,nts with myelodysplastic syndromes (MDS), suggesting that
genesis. We generated amurinemodel of themost common
opoietic phenotypes and pre-mRNA splicing alterations that
ncordant changes in isoform expression of RNA processing
loid cancers in the mouse and human highlight cellular pro-
t U2AF1-associated diseases. Determining whether splicing
ated spliceosome gene mutations may further prioritize key
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Figure 1. Global Alterations in Pre-mRNA Splicing Are Distinct in
AML Patients with U2AF1 Mutations
Unsupervised principal component analysis of standardized splicing ratios of
expressed 30 splice sites of cassette and mutually exclusive exons (greater
than five reads in half or more of samples) in patients with AML (n = 6 mutant
U2AF1[S34F/Y], green dots; n = 102 normal for spliceosome genes, gray dots;
n = 1 U2AF1[Q157P], blue dot; n = 1 SF3B1[K700E], red dot). Putative spli-
ceosome genes were used to denote ‘‘normal’’; see also Table S1.2013). U2AF1 mutations have also been identified across major
cancer types, including AML, lung adenocarcinoma, head and
neck squamous cell carcinoma, uterine corpus endometrial
carcinoma, bladder urothelial carcinoma, breast adenocarci-
noma, and colorectal carcinoma, further implicating U2AF1
broadly in cancer pathogenesis (Kandoth et al., 2013). During
normal pre-mRNA splicing activity, the U2AF1 protein binds to
the AG dinucleotide at the 30 end of the intron, thereby assisting
its cofactor U2AF2 in recruitment of the U2 snRNP for spliceo-
some activation as part of the spliceosome E/A complex (Wahl
et al., 2009; Wu et al., 1999).
It is unknown how U2AF1 mutations contribute to MDS path-
ogenesis. Several groups have reported splicing changes in cells
expressing mutant U2AF1, including cell lines (HeLa, K562),
primary human CD34+ cells, and patient AML and MDS cells
(Brooks et al., 2014; Graubert et al., 2012; Ilagan et al., 2014;
Okeyo-Owuor et al., 2014; Przychodzen et al., 2013; Yoshida
et al., 2011). However, the downstream targets of mutant
U2AF1 identified in these studies are variable, perhaps due to
differences in cell types, co-occurring mutations, and experi-
mental methods used. Initial in vivo studies using a retroviral
overexpression model showed that mouse bone marrow cells
expressing mutant U2AF1 have reduced repopulation ability
(Yoshida et al., 2011). Together, these data lead us to hypothe-
size that mutant U2AF1-induced splicing alterations and subse-
quent changes in gene isoform expression result in abnormal
hematopoiesis.632 Cancer Cell 27, 631–643, May 11, 2015 ª2015 Elsevier Inc.RESULTS
Splicing Is Altered in Primary Human AML Cells
Expressing Mutant U2AF1
To examine the effects of U2AF1mutations on global splicing in
primary patient samples, we used RNA-seq data from the The
Cancer Genome Atlas (TCGA) AML cohort (Cancer Genome
Atlas Research Network, 2013). We identified eight samples
with a spliceosome gene mutation, including six samples with
a U2AF1 mutation affecting the S34 amino acid (four S34F,
two S34Y), one sample with U2AF1(Q157P), one sample with
SF3B1(K700E), and 102 samples without a mutation or copy
number alteration in spliceosome genes (Table S1). Unsuper-
vised clustering using the splicing ratio of cassette and mutually
exclusive exon splice junctions segregated the six mutant
U2AF1(S34) patient samples from the 102 control, the
U2AF1(Q157P), and SF3B1(K700E) samples (Figure 1), indi-
cating that splicing is distinctly altered in primary patient cells
with U2AF1 mutations affecting the S34 amino acid.
Generation of U2AF1(S34F) Transgenic Mice
To study the in vivo consequences of U2AF1 mutations on
splicing and hematopoiesis in an isolated genetic system and
to prioritize splicing alterations identified in primary patient
samples, we created a mouse model to study the most abun-
dant U2AF1 mutation found in MDS patients [U2AF1(S34F)].
Using a previously-validated, single-copy, site-specific integra-
tion approach (Beard et al., 2006), we generated doxycycline-
inducible U2AF1(S34F) and control U2AF1(WT) transgenic
mice. We integrated human cDNA (human and mouse U2AF1
proteins differ in only one amino acid in the polyglycine tract
of the C-terminal RS domain) coding for U2AF1(S34F) or
U2AF1(WT) into the Col1a1 locus of KH2 mouse embryonic
stem (ES) cells (Figure S1A). KH2 ES cells contain the M2rtTA
tetracycline-responsive transactivator protein (rtTA) ubiqui-
tously expressed from the Rosa26 locus, which allows for in-
duction of the integrated U2AF1(S34F) or U2AF1(WT) transgene
following treatment of cells with the tetracycline derivative
doxycycline (Figure 2A). Integration was validated in both
mouse lines by Southern blot analysis (Figure 2B). These trans-
genic mouse lines display dose-dependent, inducible, in vivo
expression of the integrated U2AF1 transgene (S34F or WT)
in bone marrow cells (Figure 2C). For subsequent experiments,
we used a doxycycline dose (625 ppm doxycycline chow) that
induced levels of exogenous transgene expression similar to
endogenous mouse U2af1 levels in bone marrow cells, consis-
tent with the heterozygous expression of U2AF1 mutations
in MDS patient bone marrow samples (Graubert et al., 2012).
This dose of doxycycline induced similar levels of transgene
expression in U2AF1(S34F)/rtTA and U2AF1(WT)/rtTA double
transgenic mice, as determined by pyrosequencing (data
not shown). U2AF1(WT) and U2AF1(S34F) expression was in
excess of normal mouse U2af1 expression levels, resulting
in approximately double the normal protein level in cells
(Figure S1B); however, overexpression of human U2AF1 trans-
gene(s) at this dose of doxycycline has no impact on endoge-
nous mouse U2af1 expression (Figure S1C). U2AF1 transgene
expression was induced in myeloid and lymphoid cell lineages,
as well as in stem and progenitor cells (Figure S1D).
Figure 2. Generation of Doxycycline-Inducible U2AF1 Transgenic
Mice
(A) Schematic of doxycycline-inducible U2AF1 transgene system. Human
U2AF1(S34F) or U2AF1(WT) cDNAwas integrated into amodifiedCol1a1 locus
of mouse ES cells containing the reverse tetracycline transactivator (M2rtTA)
expressed from the Rosa26 locus. Addition of doxycycline induces U2AF1
transgene expression.
(B) Southern blot of ES cell or transgenic mouse tail genomic DNA using the 50
Col1a1 probe to detect the integration of U2AF1(S34F) or U2AF1(WT) trans-
genes. Flip-in of the pBS31’ vector is detected by the appearance of a 4.1 kb
band. Frt is themodified frt locus (6.7 kb), andWT is thewild-type locus (6.2 kb).
(C) Doxycycline-dose response curve of U2AF1 transgene expression relative
to endogenous mouse U2af1 in bone marrow cells measured by RT-PCR
followed by pyrosequencing assay (n = 2–7). Data are represented as
mean ±SD. The 625 ppm doxycycline chow (*) was used in all subsequent
experiments; ppm, parts per million.
See also Figure S1.Hematopoietic Cell Lineage Is Altered in U2AF1(S34F)-
Recipient Mice
To examine the cell-autonomous effects of mutant U2AF1(S34F)
expression on hematopoiesis, we transplanted transgenic
mouse bone marrow into lethally-irradiated wild-type congenic
recipient mice, allowing for R6 weeks of engraftment prior
to induction of the transgene. Initial experiments were conduct-
ed with all six possible genotypes produced from transgenic
colonies. Control genotypes of wild-type (nontransgenic) mice,
single transgenic rtTA-only, U2AF1(WT)-only, and U2AF1(S34F)-only, and double transgenic U2AF1(WT)/rtTA mice were similar
in parameters measured (Figure S2A). Given the similarity of all
controls, subsequent experiments were performed with the
U2AF1(S34F)/rtTA double transgenic mice and two control
genotypes: U2AF1(WT)/rtTA double transgenic mice and single
transgenic rtTA-only mice (littermates from the U2AF1[S34F]
transgenic mouse colony).
Examination of hematopoietic compartments in recipient mice
following one month of doxycycline to induce transgene ex-
pression revealed a reduction in peripheral blood total white
blood cell (WBC) counts in U2AF1(S34F)/rtTA-recipient mice
compared to U2AF1(WT)/rtTA- and rtTA only-recipient controls
(4.3 versus 7.11 and 7.13 K/ml, respectively, p = 0.014) (Fig-
ure 3A), but no difference in red blood cell parameters or platelet
counts (Figure S2B). This peripheral blood leukopenia was stable
and persisted for up to 12 months (Figure 3A); it was also
dependent on mutant U2AF1 expression, since the WBC counts
in mutant U2AF1(S34F)/rtTA-recipient mice recovered to levels
similar to U2AF1(WT)/rtTA-recipient mice after halting doxycy-
cline treatment, even after 6 months of transgene expression
(Figure S2C). Flow cytometry analysis of mature lineage cells in
the peripheral blood revealed a reduction in B cells and mono-
cytes in U2AF1(S34F)/rtTA-recipient mice compared to controls
(Figure 3B).
There were no differences in bone marrow cellularity or
spleen weights in U2AF1(S34F)/rtTA-recipient mice compared
to controls (Figure S2D). However, mature cell lineage distribu-
tion was altered in the bone marrow of U2AF1(S34F)/rtTA-recip-
ient mice after one month of doxycycline. Both monocytes and
B cells were reduced in U2AF1(S34F)/rtTA-recipient mouse
bone marrow, and neutrophils were increased (Figure 3C). The
reduction of monocytes in the bone marrow of U2AF1(S34F)/
rtTA-recipient mice occurred as soon as 5 days after transgene
induction (Figure S2E) and was associated with an increase in
Annexin V+ and phospho-H2AX staining of monocytes (Fig-
ure 3D). In vitro culture of transgenic mouse bone marrow re-
vealed a similar trend in Annexin V+ and phospho-H2AX flow
cytometry in U2AF1(S34F)/rtTA-expressing cells compared to
controls (Figure S2F). There was no evidence of bone marrow
dysplasia in U2AF1(S34F)/rtTA-recipient mice (Figure S2G).
The overall survival of U2AF1(S34F)/rtTA- and U2AF1(WT)/
rtTA-recipient mice was similar (Figure S2H), and mutant mice
did not develop MDS or AML after at least 1 year of continuous
doxycycline.
U2AF1(S34F)-RecipientMiceHave IncreasedProgenitor
Cells in Bone Marrow and Spleen, but Stem Cells Have a
Competitive Disadvantage in Repopulation Assays
Following 1 month of doxycycline to induce transgene expres-
sion, U2AF1(S34F)/rtTA-recipient mice displayed an increased
frequencyofmyeloidprogenitors inbothbonemarrow (Figure 4A)
and spleen (Figure 4B) by progenitor colony forming assay
(CFU-C) compared to U2AF1(WT)/rtTA- and rtTA-only-recipient
controlmice. This increasewas also seenby flowcytometry anal-
ysis for c-Kit+/lineage (KL) cells in thebonemarrow (FigureS3A),
as well as for common myeloid progenitors (CMP) in bone
marrow (Figure 4C) and spleen (Figure 4D) of U2AF1(S34F)/
rtTA-recipient mice compared to controls. Granulocyte/macro-
phage progenitors (GMP) were variably increased (Figure S3B)Cancer Cell 27, 631–643, May 11, 2015 ª2015 Elsevier Inc. 633
Figure 3. Mature Hematopoietic Cell Line-
ages Are Altered by In Vivo Expression of
U2AF1(S34F)
(A) Peripheral blood white blood cell counts of mice
transplanted with transgenic donor marrow
following 1, 6, and 12 months of doxycycline in-
duction of transgene expression (n = 5–12).
(B) Absolute count of peripheral blood monocytes
(Gr-1+, CD115+), neutrophils (Gr-1+, CD115), B
cells (B220+), and T cells (CD3e+) based on WBC
and flow cytometry following 1 month doxycycline
(n = 9–11).
(C) Mature lineage distribution of bone marrow
cells by flow cytometry for monocytes, neutrophils,
B cells, and T cells following 1 month doxycycline
(n = 9–11).
(D) Detection of apoptosis in bone marrow mono-
cytes (Gr-1+, CD115+) following 5 days of doxy-
cycline by flow cytometry for Annexin V+ (left,
n = 9–14) and intracellular phospho-H2AX (right,
n = 8–13). All data are represented asmean ±SD. *p
% 0.05, **p % 0.01, ***p % 0.001; MFI, mean
fluorescence intensity.
See also Figure S2.and megakaryocyte/erythroid progenitors (MEP) were un-
changed in mutant mice compared to controls (Figure S3C).
Flow cytometry for the stem cell-enriched compartment
defined by c-Kit+/lineage-/Sca-1+ (KLS) cells also showed an
increase in the bone marrow of U2AF1(S34F)/rtTA-recipient
mice compared to controls (Figure 4E) following 1 month of
doxycycline. Further characterization of stem cells by flow cy-
tometry using SLAM and CD34/Flk2 revealed a trend toward
increased multipotent progenitors, but no difference in short-
term and long-term stem cell populations (Figure S3D). The
increase in bone marrow stem-enriched and progenitor cells
(KLS, KL, CMP) measured by flow cytometry and by CFU-C in
U2AF1(S34F)/rtTA-recipient mice was detectable following
only 5 days of doxycycline exposure (Figures S3E–S3H). The634 Cancer Cell 27, 631–643, May 11, 2015 ª2015 Elsevier Inc.increased frequency of KLS cells after
5 days of transgene inductionwas associ-
ated with increased Ki67+ staining in KLS
cells from U2AF1(S34F)/rtTA-recipient
mice compared to controls (Figure 4F); a
similar trend was seen for BrdU incorpo-
ration (Figure S3I). There was no increase
in hematopoietic stem-enriched and
progenitor cells measured by flow cy-
tometry and methylcellulose in the
absence of doxycycline in U2AF1(S34F)/
rtTA-recipient mice (Figures S3E, S3G,
and S3H), confirming this early phenotype
at 5 days was not due to doxycycline-in-
dependent transgene expression. Next,
we evaluated stem cell function using a
competitive repopulation assay. Although
we observed an increase in the fre-
quency of stem-enriched and progenitor
cells in mutant U2AF1-recipient mice,
competitive repopulation assays revealeda disadvantage for U2AF1(S34F)/rtTA-expressing stem cells
compared to U2AF1(WT)/rtTA-expressing cells in primary recip-
ient mice (Figure 4G). The competitive disadvantage was sus-
tained when the bonemarrow from primary recipients was trans-
planted into secondary and tertiary recipient mice (Figure 4H).
Comprehensive RNA Sequencing of U2AF1(S34F)-
Expressing Mouse Bone Marrow Progenitors Reveals
Splicing Alterations
MDSpatient bonemarrow samples have an increased fraction of
common myeloid progenitors (CMPs) compared to normal bone
marrow donors (Pang et al., 2013; Woll et al., 2014), and we
observed an increase in CMPs in mutant U2AF1 mouse bone
marrow as early as 5 days following doxycycline exposure with
Figure 4. Hematopoietic Stem-Enriched
andProgenitor Cells Are Increasedby In Vivo
Expression of U2AF1(S34F) but Have a
Competitive Disadvantage in Repopulation
Assays
(A and B) Myeloid progenitor colony forming
CFU-C assays of bone marrow (A, n = 9–11) and
spleen cells (B, n = 5–10) from mice transplanted
with transgenic donor marrow following 1 month of
doxycycline.
(C and D) Flow cytometry for donor-derived com-
mon myeloid progenitors (CMP: CD45.1,
CD45.2+, lin, c-Kit+, Sca-1, CD34+, Fcg) in
bone marrow (C, n = 9–11) and spleen (D, n = 5–6)
ofmice transplantedwith transgenic donormarrow
following 1 month of doxycycline.
(E) Flow cytometry for donor-derived, stem-cell en-
riched fractions of bone marrow (KLS: CD45.1,
CD45.2+, lin, c-Kit+, Sca-1+ cells [n = 9–11])
following 1 month of doxycycline. Representative
flow cytometry plots of U2AF1(WT)/rtTA and
U2AF1(S34F)/rtTA-recipientmice showingc-Kit and
Sca-1 antigen expression on CD45.2+, lin gated
cells (left); quantification of multiple mice (right).
(F) Intracellular flow cytometry of Ki67+ levels in
bone marrow KLS cells following 5 days of doxy-
cycline (n = 9).
(G) Peripheral blood chimerism of primary recipient
mice transplanted with equal portions of trans-
genic (CD45.2+) and wild-type (CD45.1+/CD45.2+)
bone marrow cells in competitive repopulation
assays. Data are shown as fold change of trans-
genic (CD45.2+ chimerism) from the start of
doxycycline (n = 5–12). Differences (two-way
ANOVA) are indicated at each time point as
different from the U2AF1(S34F) genotype by *wild-
type nontransgenic mice, FrtTA only, and
εU2AF1(WT)/rtTA.
(H) Bone marrow cells from primary recipient mice
of the same genotype were pooled equally and
transplanted into secondary recipient mice (left,
n = 3–5); likewise, bone marrow from secondary
recipients was transplanted into tertiary recipient
mice (right, n = 4–5). Fold change of transgenic
cells (CD45.2+ chimerism) measured in peripheral
blood R4 months post-secondary and tertiary
transplants.
All data are represented as mean ± SD, except
those in (C), which are represented as mean ±
SEM. *p % 0.05, **p % 0.01, ***p % 0.001. See
also Figure S3.aconcomitant increase inCFU-C formation. Therefore,we sorted
donor-derived CMPs from U2AF1(S34F)/rtTA- and U2AF1(WT)/
rtTA-recipient mice following 5 days of transgene induction and
performed transcriptome sequencing (RNA-seq) to detect
U2AF1(S34F)-induced splicing alterations. The levels of trans-
gene induction were similar among samples (Figure S4A). On
average, CMP samples yielded 3.23 108 sequencing reads (Fig-
ure S4B), with an average of 2.0 3 108 uniquely mapped reads
across samples (Figure S4C). The distribution of reads from
various species of RNA was similar, with mutant samples having
a slightly higher percentage of intergenic bases (p < 0.05) and
lower percentage of coding bases (p = 0.05) (Figure S4D).
Unsupervised clustering based on the splicing ratio of
cassette and mutually exclusive exon junctions segregatedU2AF1(S34F)-expressing CMP samples from U2AF1(WT) con-
trols (Figure 5A), as it did for patients with AML (Figure 1). DESeq
(Anders and Huber, 2010), an algorithm that accounts for RNA-
seq replicate data and biologic variation, identified changes
in overall gene expression in 128 genes (FDR < 0.1) in
U2AF1(S34F)/rtTA samples compared to U2AF1(WT)/rtTA con-
trols (Table S2). Using these genes, we performed gene set
enrichment and pathway analyses with GOseq (Young et al.,
2010) and identified an enrichment of genes involved in immune
response and leukocyte activation processes (FDR < 0.1)
(Table S3).
DEXSeq (Anders et al., 2012), an algorithm that identifies
altered junctions while accounting for changes in overall
gene expression, identified 742 splicing junctions that wereCancer Cell 27, 631–643, May 11, 2015 ª2015 Elsevier Inc. 635
Figure 5. U2AF1(S34F) Expression Alters
Splicing in Mouse Progenitors Cells In Vivo
(A) Unsupervised principal component analysis of
standardized splicing ratios of expressed 30 splice
sites of cassette and mutually exclusive exons
(greater than five reads in half or more of samples)
in donor-derived bone marrow common myeloid
progenitor cells (CMP) sorted from mice trans-
planted with U2AF1(S34F)/rtTA or U2AF1(WT)/
rtTA bonemarrow (n = 3 pools of five to sevenmice
each) following 5 days doxycycline.
(B) Pathways enriched (GOseq FDR < 0.1) in
differentially spliced genes in U2AF1(S34F)/rtTA
CMPs.
(C) The consensus sequence surrounding the AG
dinucleotide of the 30 splice site of 544 randomly
selected junctions not altered by U2AF1(S34F).
(D and E) The 30 splice site consensus sequence of
U2AF1(S34F)-skipped exons (D, n = 156) and of
skipped canonical splice junctions and their
associated alternative 30 junctions (E, n = 42)
identified by DEXSeq (FDR < 0.1).
Results are depicted in Logos plots. ss, splice site.
See also Figure S4 and Tables S2, S3, and S4.differentially expressed in 633 genes in U2AF1(S34F)/rtTA sam-
ples compared to U2AF1(WT)/rtTA controls (FDR < 0.1) (Table
S4). Using these 633 genes, we again performed gene set
enrichment and pathway analyses and identified an enrichment
of genes involved in RNA binding (FDR < 0.1) (Figure 5B). The
majority of differentially spliced junctions in U2AF1(S34F)/rtTA
samples compared to U2AF1(WT)/rtTA controls were classified
as cassette exon, simple alternative 30 splice acceptor site,
and coordinate cassette exon events (Figure S4E).
U2AF1(S34F) Has Altered 30 Splice Acceptor Sequence
Preference
To further examine the effects of U2AF1(S34F) expression on
splicing in vivo, we determined the consensus sequence flanking
the AG dinucleotide at the 30 splice acceptor site known to be636 Cancer Cell 27, 631–643, May 11, 2015 ª2015 Elsevier Inc.recognized by U2AF1 during splicing
(Wu et al., 1999). In contrast to the
sequence motif seen in non-dysregulated
control junctions (Figure 5C), exons
skipped more frequently by mutant
U2AF1(S34F) relative to U2AF1(WT)
were enriched for uracil (indicated by a
T) in the 3 position relative to the AG
dinucleotide (Figure 5D). We observed a
similar pattern in alternative 30 splice site
usage; there is an enrichment of T in the
3 position of canonical 30 splice sites
whose alternative 30 splice site was used
more frequently in mutant U2AF1(S34F)/
rtTA samples relative to U2AF1(WT)/rtTA
controls (Figure 5E). This pattern is
the same as seen in AML patient sam-
ples with U2AF1 mutations and in pri-
mary human CD34+ cells expressing
U2AF1(S34F) or U2AF1(WT), and similarto previously reported data in human samples (Brooks et al.,
2014; Ilagan et al., 2014; Okeyo-Owuor et al., 2014; Przychodzen
et al., 2013). These data indicate that the sequence-specific
pattern of altered splicing induced by mutant U2AF1 is similar
in mouse and human cells.
U2AF1(S34F)-Induced Splicing Changes Are Enriched
in Genes Involved in RNA Processing and Splicing,
Protein Translation, and Recurrently Mutated Genes
in MDS/AML
To prioritize altered splicing events for further analysis, we inter-
sected significant junctions (DEXSeq; FDR < 0.1) across three
datasets: mouse CMP samples (n = 219 junctions), AML patient
samples with and without U2AF1 mutations (n = 162 junctions),
and our previously described primary human CD34+ cells
Figure 6. Mutant U2AF1 Alters Splicing in Common Targets across Species
(A) Venn diagram of the overlap of independently discovered mutant U2AF1-induced splice junction changes by DEXSeq analysis (FDR < 0.1) in three RNA-seq
datasets: transgenic mouse CMPs, primary human hematopoietic CD34+ cells, and human AML patient samples. *Indicates multiple significant junctions
detected within the gene.
(B) Correlation plots and r values for junctions identified by overlap of DEXSeq datasets shown in the Venn diagram. One junction per gene is shown.
(C) Log2 fold change in junction expression [U2AF1(WT) versus U2AF1(S34F)] for overlapping genes (A) and recurrently mutated genes inMDS and AML identified
by Fisher’s meta-analysis (Table 1), plotted in descending order based on CMP results. U2AF1 was excluded due to an inability to differentiate endogenous
versus exogenous U2AF1(WT) transcript in CD34+ cells.
See also Figure S5 and Tables S5 and S6.overexpressing U2AF1(S34F) or U2AF1(WT) (n = 1,652 junctions)
(Okeyo-Owuor et al., 2014). The intersection was (necessarily)
composed of homologous junctions and was additionally re-
stricted to include only concordantly dysregulated (same direc-tion of log fold change) junctions; 17 homologous dysregulated
junctions (p < 0.0001; simulation) were present in 13 genes (Fig-
ures 6A and 6B). Several of the dysregulated junctions corre-
sponded to the same splicing event in a transcript and wereCancer Cell 27, 631–643, May 11, 2015 ª2015 Elsevier Inc. 637
Table 1. Spliceosome and Recurrently MutatedMDS/AMLGenes
with Dysregulated Splicing
Spliceosome Genes Recurrently Mutated Genes inMDS/AML
CLK1 AKAP13
CLK3 ARAP2
CPSF4 BCOR
HNRNPA1 DIS3
HNRNPA2B1 GNAS
HNRNPC KDM6A
HNRNPD KMT2D
HNRNPH1 NCOR1
HNRNPM NPM1
PCBP2 SCARB1
PRPF40A SRSF2
PTBP1 U2AF1
PTBP2 U2AF2
RBM39 ZC3H18
RNMT
SF3B3
SNRNP70
SNRPG
SRSF10
SRSF11
SRSF2
SRSF7
TCERG1
THOC1
THOC2
U2AF1
U2AF1L4
U2AF2
YBX1
ZMAT2
Fisher FDR < 0.1. See also Table S7.identified as reciprocal splice junctions. All of these junctions
occur in known isoforms, though the function of most of these
isoforms remains largely unknown. Several of these junctions
occur in genesmutated inMDS and AML (GNAS, PICALM) (Bejar
et al., 2011; Borel et al., 2012) or known to be involved in stem
cell biology (H2AFY, MED24) (Buschbeck et al., 2009; Chia
et al., 2010; Gaspar-Maia et al., 2013).
To broaden the list of potentially concordant changes across
species, we performed a meta-analysis of the three indepen-
dent datasets using Fisher’s combined probability test (Brown,
1975) and identified 555 significantly dysregulated homolo-
gous junctions in 415 genes across all three datasets (FDR <
0.1) (Table S5). The larger number of dysregulated junctions
relative to the conservative intersection above enables both
consensus sequence analysis and pathway/gene-set enrich-
ment analyses. Skipped exons from the Fisher dataset also
show an enrichment of T at the 3 position of 30 splice sites,
as in the CMP data (Figure S5). We hypothesized that splicing
in biologic pathway(s) could be widely disrupted by mutation of638 Cancer Cell 27, 631–643, May 11, 2015 ª2015 Elsevier Inc.an upstream splicing factor. To test this, we performed gene
set enrichment and pathway analyses on the 415 splicing-dys-
regulated genes using GOseq. This resulted in 28 pathways/
categories identified as significant (FDR < 0.1, Enrichment >
2) by one of the three independent analyses of KEGG path-
ways or GO molecular function (MF) or biological processes
(BP) categories; 14 of these contain genes involved in RNA
processing, RNA splicing, RNA localization/transport, and
RNA binding, whereas 11 were involved in protein translation
processes and ribosomal pathways (Table S6). Additionally,
spliceosome genes (p = 4.68 3 108, Table S1) and genes
recurrently mutated in MDS and AML (Bejar et al., 2011; Can-
cer Genome Atlas Research Network, 2013; Haferlach et al.,
2014; Papaemmanuil et al., 2013; Walter et al., 2013) (p =
0.03, Table S7) were enriched in the 415 splicing-dysregulated
genes (Table 1 and Figure 6C). Oncogenes and tumor sup-
pressors (Supek et al., 2014) were also highly represented
(p = 0.09, data not shown).
U2AF1(S34F)-Induced Splicing Changes Are Present in
Human MDS Bone Marrow Samples
Next, we examined MDS patient bone marrow samples for
mutant U2AF1-induced splicing changes discovered by RNA-
seq analysis in a subset of affected genes. Dysregulated splicing
events were prioritized for validation by overlap in the three data-
sets, splicing ratio change, or known biological function of the
gene, with particular focus on genes mutated in MDS. Mutant
U2AF1-induced splice isoform changes identified by RNA-seq
analysis were concordant with RT-PCR of MDS patient bone
marrow samples for seven of eight splicing events examined,
including H2AFY, BCOR, PICALM, GNAS, KDM6A, KMT2D
(MLL2), andMED24; only EIF4A2 showed no difference (Figure 7
and data not shown).
DISCUSSION
In this study, we provide evidence that mutant U2AF1 expres-
sion alters hematopoiesis and pre-mRNA splicing in the primary
hematopoietic progenitor cells of mice. U2AF1(S34F) expres-
sion in mice results in leukopenia and changes in the distribu-
tion of mature hematopoietic lineages in the peripheral blood
and bone marrow. In addition, U2AF1(S34F) expression in-
creases the frequency of progenitor cells in the bone marrow
and spleen of mice as well as the frequency of progenitor cells
that are cycling in the bone marrow. We identify U2AF1(S34F)-
specific changes in splice isoforms in 633 genes in mouse
common myeloid progenitors. Finally, through an integrative
meta-analysis of three unique RNA-seq datasets, we identify
splice junctions that are consistently altered across species
by mutant U2AF1 expression and that are enriched in RNA pro-
cessing genes, translational processes/ribosomal genes, and
recurrently mutated genes in MDS/AML. Collectively, these re-
sults suggest that U2AF1(S34F)-induced alternative splicing
may contribute to the altered hematopoiesis that is character-
istic of patients with MDS.
Mutant U2AF1(S34F) mice display several phenotypes associ-
ated with MDS, including leukopenia, increased apoptosis of
maturing cells in the bonemarrow, and progenitor cell expansion
(Catenacci and Schiller, 2005; Hamblin, 1992; Pang et al., 2013;
Raza et al., 1995a, 1995b; Shetty et al., 2000; Troy et al., 2014;
Woll et al., 2014; Yoshida, 1993). However, these mice do not
show dysplasia, nor do they develop MDS or AML. Similar to
another genetic mouse model of MDS mutations (ASXL1)
(Abdel-Wahab et al., 2013), mutant U2AF1(S34F)-expressing
stem cells appear to have a competitive disadvantage and
increased apoptosis compared to wild-type cells, highlighting
a conundrum for MDS biology: how is clonal dominance
achieved by a cell containing mutation(s) that result in reduced
competitiveness and increased apoptosis? Although U2AF1
mutations are typically early genetic events, they may occur in
cells already harboring a mutation that is permissive for clonal
expansion. Cooperativity studies with significantly co-occurring
mutations, such as del(20) or ASXL1 mutations (Bacher et al.,
2014; Damm et al., 2012; Papaemmanuil et al., 2013; Walter
et al., 2013) (or with other common mutations in MDS, like those
in TET2 or DNMT3A), may be necessary to determine whether
U2AF1 mutations require a specific genetic context to cause
MDS or AML. Ultimately, U2AF1 mutations may contribute to
ineffective hematopoiesis that is typical in MDS, whereas other
mutations confer clonal dominance. This mouse model could
be used to address these questions.
In this study, we show U2AF1(S34F)-induced splicing alter-
ations in primary hematopoietic cells in an isolated genetic sys-
tem in vivo. By using primary mouse CMPs and human CD34+
cells, we capitalize on identifying early splicing changes that
are induced by mutant U2AF1 expression in the absence of
transformation. Importantly, expression of mutant U2AF1 in
mouse bone marrow cells results in an altered 30 splice acceptor
site sequence preference that is identical to the pattern observed
in human cells, suggesting that the same mechanism of altered
splicing is conserved across species and credentialing the
mouse model for mechanistic studies.
We identified a list of consistently altered candidate genes that
may contribute tomyeloid disease pathogenesis. Comparison of
these datasets with dysregulated junctions found in lung adeno-
carcinoma patient samples with U2AF1mutations suggests that
at least some genes with altered splicing are shared across
cancer and cell types harboring U2AF1 mutations; indeed, 13
of 29 genes with significant alterations associated with U2AF1
mutations in both lung adenocarcinoma and AML are also pre-
sent in our list of junctions identified by meta-analysis (Brooks
et al., 2014).
Further studies will be needed to identify the consequences of
mutant U2AF1-induced splicing alterations for hematopoiesis
and myeloid disease. It is still unknown if the contribution of
U2AF1mutations toMDS pathology involves pre-mRNA splicing
alterations of one, a select few, or many genes of interest. Future
rescue experiments using target mRNAs/shRNAs to alter iso-
form expression in mice will be necessary to address this ques-
tion. However, the observation that dysregulated splicing
junctions induced by mutant U2AF1(S34F) are enriched in recur-
rently mutated genes in MDS/AML raises the possibility that
subtle changes in isoform expression in one or more genes
may contribute to mutant U2AF1-associated disease. Changes
in isoform expression of cancer-associated genes may have
important consequences for a cell. For example, different iso-
forms of NRAS have been shown to activate different signaling
molecules, and expression of a rare isoform results in increasedcell proliferation and transformation when compared to other
NRAS isoforms (Eisfeld et al., 2014). We identified consistent
splicing alterations in several genes commonly affected by loss
of function mutations in MDS and cancer, including BCOR and
KDM6A; however, splicing changes in both genes resulted in
frame-preserving isoforms. Although the functional conse-
quences of these changes are unknown, the dysregulated iso-
form of BCOR has been shown to lack a domain necessary to
interact with the transcription factor AF9 (a common fusion part-
ner of MLL) and repress AF9 transcriptional activity (Srinivasan
et al., 2003).
We report here that perturbations in spliceosome and RNA
processing genes occur in three independent mutant U2AF1
RNA-seq datasets. It raises the possibility that mutation of a spli-
ceosome gene may result in autoregulatory changes in splicing
machinery by altering isoform expression (Jangi and Sharp,
2014). This may account for the mutual exclusivity of spliceo-
some gene mutations in patients with MDS (Haferlach et al.,
2014; Papaemmanuil et al., 2013; Walter et al., 2013; Yoshida
et al., 2011). Perturbations in the splicing process may have con-
sequences for genome stability, as missplicing has been impli-
cated in co-transcriptional R-loop formation (RNA:DNA hybrid)
(Chan et al., 2014; Skourti-Stathaki and Proudfoot, 2014). This
may contribute to the increased phospho-H2AX staining we
observe in monocytes by inducing DNA damage through
R-loop formation. Further studies are needed to address this.
In addition, the identification of genes involved in ribosome func-
tion and translational processes are an interesting consequence
of mutant U2AF1 expression, because perturbations in the ribo-
some have been linked to MDS (Barlow et al., 2010; Ebert et al.,
2008; Pellagatti et al., 2008). If other spliceosome gene muta-
tions (e.g., SRSF2, SF3B1) perturb either of these two pathways,
it would suggest a unifying mechanism of action for all these
mutations. Ultimately, examination of dysregulated splicing
caused by other spliceosome gene mutations and comparison
with these findings may help clarify which gene pathways are
important.
By performing all of our experiments in a cell-autonomous
manner using a transplantation model, transgenic donor bone
marrow cells necessarily undergo the stress of repopulating
the hematopoietic system in the irradiated microenvironment
of recipient mice. However, phenotypes observed in the trans-
planted mice were also seen in non-transplanted transgenic
mice, including bone marrow progenitor expansion and mono-
cyte apoptosis (data not shown). While the transgenic model
we describe here could be used to test the dependency of tu-
mors on mutant U2AF1 expression (by removing doxycycline
once tumors develop), the overexpression of U2AF1(S34F) or
U2AF1(WT) transgene, albeit low, is expected to result in
non-stoichiometric levels of U2AF1 relative to other splicing fac-
tors. However, no detectable phenotypes were observed in
U2AF1(WT)-expressing transgenic mice compared to rtTA only
controls. Additional models of U2AF1 mutations (e.g., knockin
of S34F at the endogenous U2af1 locus and mice with other
U2AF1 mutations) will be important to further characterize the
effect of U2AF1 mutations in vivo.
Although this study improves our understanding of mutant
U2AF1 biology, our ultimate goal is to improve treatment
of patients with U2AF1 mutations. The pervasive nature ofCancer Cell 27, 631–643, May 11, 2015 ª2015 Elsevier Inc. 639
Figure 7. Mutant U2AF1 Alters Splicing in
MDS Bone Marrow Cells
(A) Mutually exclusive exons inH2AFY detected by
RT-PCR and gel electrophoresis (quantified in
right); the diagram of the event measured and the
gel image (left).
(B and C) Quantification of alternative splice site
utilization (B) and altered cassette exon events (C).
All data are represented as mean ±SD. *p% 0.05,
**p% 0.01, ***p% 0.001; n = 5–6.spliceosome gene mutations in MDS highlights the need to
understand and develop effective therapeutic approaches,
perhaps by using splicing modulator drugs. This U2AF1 mouse
model may be a useful pre-clinical tool to test potential therapies
in a variety of cancers with U2AF1 mutations.
EXPERIMENTAL PROCEDURES
Generation of Doxycycline-Inducible U2AF1(S34F) and U2AF1(WT)
Transgenic Mice
cDNAs that code for humanU2AF1(S34F) andU2AF1(WT)were cloned from an
MDS patient bonemarrow sample (UPN 571656) by RT-PCR using Superscript
III kit (Invitrogen) and introduced individually into thepBS310 vector (Beardet al.,
2006) using EcoRI restriction sites. U2AF1(S34F) and (WT) cDNA sequences640 Cancer Cell 27, 631–643, May 11, 2015 ª2015 Elsevier Inc.differed only in the one nucleotide that produced
the S34F amino acid conversion. U2AF1(S34F)-
pBS310 and U2AF1(WT)-pBS310 plasmids were
introduced into KH2 ES cells by the FLP/FRT sys-
tem (Beard et al., 2006) to produce U2AF1(S34F)
and U2AF1(WT)-expressing ES cell lines. ES cell
clones were selected by hygromycin, and integra-
tion of U2AF1 (S34F) or (WT)-pBS310 was
confirmed using PCR and Southern blot ap-
proaches. Integration at the 50 end was detected
using standard Southern blotting techniques as
described (Beard et al., 2006). PCR screening of
ES cells and genotyping of mice were performed
with the primers described (see Supplemental
Experimental Procedures). KH2 ES cells are
(C57BL/6 3 129S4Sv/Jae)F1-derived V6.5 embry-
onic stem (ES) cells (Beard et al., 2006); therefore,
transgenic mouse colonies were maintained by
breeding heterozygous, doubly transgenic mice
(U2AF1(S34F)/rtTA and U2AF1(WT)/rtTA) to
(C57BL/6 3 129S4Sv/Jae)F1 mice. Doxycycline
was administered via doxycycline-containing ro-
dent chow (Pico5053base, TestDiet) or viadoxycy-
cline in water (in UV light-protected red water
bottles, changed every 2 days).
All mouse procedures were performed accord-
ing to protocols approved by the Washington Uni-
versity Animal Studies Committee.
RT-PCR and Pyrosequencing
Following doxycycline induction of transgene
expression in vivo, bone marrow cells were har-
vested from the leg bones. RNA was isolated
from bone marrow cell pellets using the RNeasy
kit (QIAGEN) followed by DNA removal with Turbo
DNA-free kit (Ambion). Reverse transcription PCR
was then performed using the Superscript III RT-
PCR kit (Invitrogen). PCR for U2AF1 and U2af1 to
detect exogenous human transgene and endoge-
nous mouse transcripts expressed in transgeniccells, respectively, was performed, and pyrosequencing for single nucleotide
polymorphisms that differ between mouse and human cDNAs was performed
on PCR products (primer sequences are listed in the Supplemental Experi-
mental Procedures).
Murine Bone Marrow Transplant and Competitive Repopulation
Assays
To generate mice for each experiment, 13 106 transgenic mouse donor bone
marrow cells from two to three mice pooled (CD45.2) were transplanted into at
least five lethally irradiated (1,100 rads) wild-type recipient mice (C57BL/6 3
129S4Sv/Jae)F1 (CD45.1/CD45.2) per genotype. Donor mice were between
8 and 12 weeks of age, and recipient mice ranged from 6 to 12 weeks of
age; donor and recipient mice were sex-matched. Competitive repopulation
assays were performed by mixing transgenic donor ‘‘test’’ mouse bone
marrow cells (CD45.2) from two to three mice in equal proportions with
(C57BL/6 3 129S4Sv/Jae)F1 (CD45.1/CD45.2) donor ‘‘competitor’’ mouse
bone marrow cells from two to three mice, and then transplanted into
(C57BL/6 3 129S4Sv/Jae)F1 (CD45.1/CD45.2) recipient mice. Transgene in-
duction was startedR6 weeks after transplantation.
Mouse Hematopoietic Progenitor Assay
Methylcellulose progenitor colony forming assays (CFU-C) were performed
using Methocult GF M3434 (Stem Cell Technologies). Bone marrow and
spleen cells were obtained from transplanted mice following doxycycline
induction of transgene expression. Red blood cells were lysed prior to
plating of 10,000 bone marrow cells or 100,000 spleen cells per 1.3 ml media;
each sample was evaluated in duplicate. Progenitor colonies (defined as
R40 cells/colony) were counted following 7 days culture at 37Cwith 5%CO2.
Flow Cytometry
Flow cytometry of donor-derived mature cell lineage distribution was per-
formed on bone marrow, peripheral blood, and spleen using the cell surface
receptors: CD45.1, CD45.2, CD115, Gr-1, B220, and CD3e (antibodies and
procedures described in the Supplemental Experimental Procedures).
Apoptosis was evaluated by flow cytometry for Annexin V (APC, BD Biosci-
ences) and intracellular Phospho-H2AX (FITC, JBW301, EMD Millipore) using
the BD Cytofix/Cytoperm kit (BD Biosciences) following the manufacturer’s
recommendations. Donor-derived hematopoietic progenitor and stem cell
flow cytometry was performed on bone marrow and spleen using the following
cell surface markers (antibodies described in the Supplemental Experimental
Procedures): CD45.1, CD45.2, mature lineage (Gr-1, Cd3e, B220, Ter119, and
CD41), c-Kit, Sca-1, CD34, Fcg, CD150, CD48, and Flk2. All flow cytometry
was performed using FACScan or Gallios cytometers (BD Biosciences) and
analyzed using FlowJo software (FlowJo). Progenitor cells were isolated for
RNA-seq using an iCyt Synergy flow sorter (Sony).
RNA Sequencing of Common Myeloid Progenitors
Donor-derived common myeloid progenitors (CMPs; lin-, c-Kit+, Sca-1,
CD34+, Fcg) cells were sorted from pooled bone marrow of five to seven
U2AF1(S34F)/rtTA- or U2AF1(WT)/rtTA-transplanted mice. Cells were sorted
into DMEM media, and RNA was prepared from cell pellets using a miRNeasy
kit (QIAGEN). Genomic DNA was removed by Turbo DNA-free kit (Ambion). Ri-
bosomal RNA was depleted (Ribozero, Epicenter), followed by cDNA prepara-
tion and TruSeq stranded Illumina library production; 2 3 100 bp paired-end
sequencing was performed on the HiSeq2000 platform (Illumina).
RNA-Seq Analysis
Reads were aligned to the mouse mm9 reference genome using TopHat
(version 2.0.8) (Kim et al., 2013). All subsequent analyses were performed in
R (Gentleman et al., 2004). Differential gene expression was determined using
DESeq2 (version 1.6.1) (Anders and Huber, 2010), which applies a negative
binomial model to counts of reads mapped to genes. Gene models were pro-
vided by Ensembl version 67 (Flicek et al., 2013). Differential junction expres-
sion was determined using DEXSeq (version 1.12.1) (Anders et al., 2012),
which applies a negative binomial model to (novel or Ensembl-annotated)
junction-spanning read counts while controlling for potential changes in overall
gene expression between conditions. Gene enrichment analysis was per-
formed using GOseq (version 1.18.0) (Young et al., 2010), which accounts
for gene-length induced biases. Regions spanning junctions were downloaded
from the UCSC Genome Browser (Kent et al., 2002) using BSgenome (version
1.34.0), and their sequence logos were created using seqLogo (1.32.1). Prin-
cipal component analysis was performed using prcomp, with normalization
performed by ggbiplot (version 0.55). Additional bioinformatic analysis of
RNA-seq data, including splicing ratio calculation, is described in the Supple-
mental Experimental Procedures.
RT-PCR and Gel Electrophoresis for Validation of Discovered
Altered Junctions
RNA extraction from MDS patient samples, cDNA preparation, and RT-PCR
followed by gel electrophoresis were carried out as described elsewhere
(Okeyo-Owuor et al., 2014). Briefly, total RNA was treated with DNase using
the Turbo DNA-free kit (Ambion), and cDNA was generated using the Super-
script III reverse transcriptase kit (Invitrogen). PCR products were electrophor-esed in TBE-polyacrylamide gels and stained with ethidium bromide for
imaging. Densitometry was performed using ImageJ. PCR primers are
described in the Supplemental Experimental Procedures.
All patients provided written consent on a protocol approved by the
Washington University Human Studies Committee.
Statistical Analyses
Statistical analysis and generation of graphical presentations of data were
performed using analysis functions in GraphPad Prism 6 and as described in
the Supplemental Experimental Procedures for RNA-seq analysis.
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